Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Huys

Showing results (81-90 of 206) with videos related to

Pageof 21
Sort By:
Orphanet Journal of Rare Diseases|December 9, 2022
Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case studyKhadidja Abdallah, Kathleen Claes, Isabelle Huys, et al.
Frontiers in Pharmacology|April 25, 2024
Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooksThomas Desmet, Maud Brijs, Frank Vanderdonck, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 29, 2004
Novel conopeptides of the I-superfamily occur in several clades of cone snailsSilke Kauferstein, Isabelle Huys, Ulrich Kuch, et al.
Applied Health Economics and Health Policy|July 31, 2019
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian PopulationKim Pauwels, Isabelle Huys, Minne Casteels, et al.
Frontiers in Medicine|January 22, 2025
Unmet medical needs definition and incentives: stakeholders perspectives on the reform of the EU pharmaceutical legislationIo Wens, Zilke Claessens, Alice Vanneste, et al.
Therapeutic Innovation & Regulatory Science|September 6, 2025
Future-Proofing European Pharmaceutical Regulatory and Market Access Practices Based on EU Learnings from the COVID-19 Pandemic: Insights from Multi-Stakeholder InterviewsZilke Claessens, Grace Beirne, Catherine Decouttere, et al.
Frontiers in Pharmacology|May 8, 2023
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trendsElif Car, Arnold G Vulto, Mark Van Houdenhoven, et al.
Frontiers in Pharmacology|May 6, 2021
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape AnalysisYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Orphanet Journal of Rare Diseases|May 6, 2019
Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in BelgiumLiese Vandeborne, Eline van Overbeeke, Marc Dooms, et al.
Expert Opinion on Biological Therapy|March 1, 2025
Drawing on collective action theory to foster sustainable biosimilar markets - insights from co-creation workshops with UK and Belgian stakeholdersTeresa Barcina Lacosta, Arnold G Vulto, Florian Turk, et al.
Pageof 21

Showing results (81-90 of 206) with videos related to

Sort By:
Pageof 21
Orphanet Journal of Rare Diseases|December 9, 2022
Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case studyKhadidja Abdallah, Kathleen Claes, Isabelle Huys, et al.
Frontiers in Pharmacology|April 25, 2024
Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooksThomas Desmet, Maud Brijs, Frank Vanderdonck, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 29, 2004
Novel conopeptides of the I-superfamily occur in several clades of cone snailsSilke Kauferstein, Isabelle Huys, Ulrich Kuch, et al.
Applied Health Economics and Health Policy|July 31, 2019
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian PopulationKim Pauwels, Isabelle Huys, Minne Casteels, et al.
Frontiers in Medicine|January 22, 2025
Unmet medical needs definition and incentives: stakeholders perspectives on the reform of the EU pharmaceutical legislationIo Wens, Zilke Claessens, Alice Vanneste, et al.
Therapeutic Innovation & Regulatory Science|September 6, 2025
Future-Proofing European Pharmaceutical Regulatory and Market Access Practices Based on EU Learnings from the COVID-19 Pandemic: Insights from Multi-Stakeholder InterviewsZilke Claessens, Grace Beirne, Catherine Decouttere, et al.
Frontiers in Pharmacology|May 8, 2023
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trendsElif Car, Arnold G Vulto, Mark Van Houdenhoven, et al.
Frontiers in Pharmacology|May 6, 2021
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape AnalysisYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Orphanet Journal of Rare Diseases|May 6, 2019
Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in BelgiumLiese Vandeborne, Eline van Overbeeke, Marc Dooms, et al.
Expert Opinion on Biological Therapy|March 1, 2025
Drawing on collective action theory to foster sustainable biosimilar markets - insights from co-creation workshops with UK and Belgian stakeholdersTeresa Barcina Lacosta, Arnold G Vulto, Florian Turk, et al.
Pageof 21